Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Farewell to Bioinformatics | Main | AstraZeneca's Nasty Numbers »

January 31, 2013

Mipomersen Approved (Bonus Antisense Roundup Included)

Email This Entry

Posted by Derek

So Isis and their partner Sanofi have received FDA approval for mipomersen (branded as Kynamro). Late last year, the European Medicines Agency turned them down, which has people wondering about the drug's future, but here they are, albeit with a warning on the label about liver toxicity.

Mipomersen is designed to lower the Apo-B lipoprotein in people with the most severe (homozygous) form of familial hypercholesterolemia. That's a small patient population, but they're definitely in need of help. The really significant thing about this approval, in my mind, is that it's a pure antisense therapy, and it comes about twenty years after there was supposed to be a world-changing flood of them. (Isis did get one through the process back in 1996, fomivirsen, but it's never had much of an impact). It was a standing joke back in the late 1980s/early 1990s that everyone had heard from a headhunter recruiting for one antisense company or another. (Sheesh, those were the days, eh? There still are search firms, right? When's the last time a headhunter rang your phone?)

I don't think that mipomersen will ever reach the heights that Isis thought it might a few years ago; the liver tox problems will see that it's only used in life-threatening situations. (I note that one time when I wrote about the drug, fans of ISIS showed up rolling their eyes at the mistaken notion that liver tox could ever be a problem). But I'm divided between congratulating them on finally getting something onto the market, and wondering about how difficult it's been to get there. As far as I know, the liver tox seen in this case is largely (completely?) thought to be due to the mechanism of action on lipid handling in the liver itself.

So how about the other antisense compounds in the clinic? As of that 2010 link above, we had trabedersen, for TGF-beta2, which is actively being tried against pancreatic cancer. Alicaforsen, for Crohn's et al., has shown disappointing efficacy in Crohn's, but is still alive for ulcerative colitis.. Aganirsen, for various vascular conditions in the eye, is still in development, with more funding having arrived recently. Oblimersen has shown some effects in the clinic, but CLL is a crowded area, and its current status is unclear, at least to me. And custirsen is in Phase III, with mixed results in Phase II trials.

Actually, that lineup looks a lot like drug development in the rest of the industry, to be honest. Some stuff looks OK and is moving along, some not so OK, and some has wiped out. It's important to realize that even if liver tox is not some general feature of the mipomersen-generation antisense compounds, that we still have efficacy failures. Oh, that we do. The indications where we can really laser right in on a key target do not make a long list. Many of those are orphans, too. In contrast, the list of giant-unmet-medical-need indications where we can laser right in on a key target is, I think, waiting for something, anything, to be written on it.

Comments (13) + TrackBacks (0) | Category: Clinical Trials


COMMENTS

1. exGlaxoid on January 31, 2013 9:51 AM writes...

I worked on antisense (we called them non-sense) compounds many years back. We were assured that they had to be non-toxic due to their binding only to one in a billion DNA sequences.

Well, someone forgot to tell the molecules that, because in at least some cases, using non-natural DNA oligomers, as we saw some horrible liver toxicity. I scaled up one DNA oligomer to 100's of mgs in 10 mg batches (that was a serious amount of work back then) for preclinical studies, as we were told that we would need to go very high before seeing any side effects, based on cellular tox. studies.

The first batch of mice died fairly quickly from liver tox. after about 10 mg each IV. Next batch got 5 mg, and they died aften a day or two from liver tox. The lowest dose was 1 mg each, which caused a slow dead from liver failure.

I can't go into details on the structures, they were modified DNA chains, but they were commonly claimed to be very non-toxic by some biotech. companies. I think that area has since been abandoned, but while I see some great potential in anti-sense DNA, especially for diagnostics and as tool compounds, I would not believe anyone who says that they are safe based on simple tests.

After all, most cells I have seen don't have livers or kidneys, so those tests are not very meaningful in that context. And I don't know why the compounds were liver toxic, we ran from that area very quickly and quietly.

Permalink to Comment

2. ScientistSailor on January 31, 2013 10:37 AM writes...

A headhunter rang my phone yesterday, looking for people to move to China. Seriously.

Permalink to Comment

3. ErrHuman on January 31, 2013 10:41 AM writes...

@ #2 At Chinese wages or on an expat contract?

Permalink to Comment

4. Anonymous on January 31, 2013 10:49 AM writes...

Great success, go Oligos!

Permalink to Comment

5. Toad on January 31, 2013 10:49 AM writes...

For the sake of completeness, I think you should mention that another drug, lomitapide (Juxtapid), was recently approved (Dec 2012) for the same indication, albeit a different mechanism. And, it is an oral small molecule as opposed to an injected oligomer.

It's good to see both of the drugs becoming available to that population. It will be interesting to see how efficacy, side effect management, and pricing will be handled with two very different drugs in a relatively small population.

Permalink to Comment

6. Puff the Mutant Dragon on January 31, 2013 11:16 AM writes...

Very cool. Go Isis!!!

Permalink to Comment

7. Chrispy on January 31, 2013 12:22 PM writes...

@2 The last headhunter call I got was for a job in China, too. Apparently quality control is a problem.

We never got to wages because I don't want to move to China, but I'm sure for the adventurous type one could live pretty well.

Permalink to Comment

8. biotechscientist on January 31, 2013 3:19 PM writes...

I noticed that Fomivirsen has been discontinued in the US. It wasn't pulled by the FDA, but it looks like it ISIS willingly pulled it off the shelves because frequent administration was needed.

Does anyone else have insight into what happened...it was the first one.

Permalink to Comment

9. biotechscientist on January 31, 2013 3:23 PM writes...

and it wasn't selling because frequent administration was needed....Jssh...Thank God its Friday tomorrow.

Permalink to Comment

10. ScientistSailor on January 31, 2013 9:39 PM writes...

@3 and 7. I didn't even discuss details. I've been to China enough times to know I wouldn't leave a job here to go there, only if I had already eaten my savings, the shrubs in front of my house, and my car upholstery...

Permalink to Comment

11. drug_hunter on February 1, 2013 3:08 PM writes...

Where is the outrage over Derek's starting yet another post with "So" ??? Eternal vigilance, people.

Permalink to Comment

12. matt on February 2, 2013 9:44 PM writes...

Comments prize to #11 drug_hunter! That was funny.

Permalink to Comment

13. Rattus on June 19, 2013 4:31 PM writes...

Does anyone know what happened to the antisense compound AEG 35156? I can't find any clues as to why the clinical trials were all terminated. It was a 19 mer, modified ends (4,11,4). Aegera was the company. Very cold trail.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All